TrialBlood advances2018

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.

Alexander Röth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.